Search
We studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in children, 3-5 years of age, in community controls of a similar age.
We evaluated the immunogenicity and safety of 1 and 2 doses of MenACWY-TT, given alone or co-administered with PCV13 in toddlers.
We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.
Pneumonia, most often caused by a respiratory virus, is common in childhood.
The aim of our study was to characterize the activity of TNAP on TLR agonists and assess the concentrations of plasma ALP during late-onset sepsis in newborns.
All children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.
The production of functional antipneumococcal antibodies in otitisprone children demonstrates that they respond to the current pneumococcal conjugate vaccine (PCV)and are likely to respond to pneumolysin-based vaccines as effectively as healthy children.
Studies investigating pathogen-specific infectious disease would benefit from using multiple data sources.
A new study has confirmed the changing pattern of meningococcal disease in Western Australia.
Greater knowledge and understanding of National Human Papillomavirus vaccination appeared to promote positive attitudes towards vaccination